Evidence map›Paper›PMID 22816023›Full record

ArticleACS chemical neuroscience2011

Modulation of adenosine receptors by [60]fullerene hydrosoluble derivative in SK-N-MC cells.

Davide Giust, David León, Inmaculada Ballesteros-Yañez, Tatiana Da Ros, José Luis Albasanz, Mairena Martín

Abstract read
In one paragraph

Article in ACS chemical neuroscience, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 8 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Davide GiustDepartmento de Química Inorgánica y Bioquímica, Facultad de Químicas, Centro Regional de Investigaciones Biomédicas, Universidad de Castilla-La Mancha, Ciudad Real, Spain.
David León
Inmaculada Ballesteros-Yañez
Tatiana Da Ros
José Luis Albasanz
Mairena Martín
University of Castilla-La Mancha · ESUniversity of Trieste · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The most known fullerenes are spherical carbon compounds composed of 60 carbon atoms. C(60) fullerenes have shown biochemical and biomedical properties in the last years such as as blockade of apoptosis and neuroprotection. The nucleoside adenosine has a neuroprotective role mainly due to inhibition of glutamate release, which is a neurotransmitter related to excitotoxicity and cell death. In the present work, we have determined the presence of adenosine receptors in SK-N-MC cells, a neuroepithelioma human cell line, and analyzed the effect of fullerenes in these receptors by using radioligand binding, immunoblotting, and quantitative real time PCR assays. Results demonstrated that SK-N-MC cells endogenously express adenosine receptors. Fullerene exposure of these cells did not affect cell viability measured by MTT reduction assay. However, adenosine A(1) and A(2A) receptors were both increased in SK-N-MC cells after treatment. These results suggest for the first time the modulation of adenosine receptors after C(60) fullerenes exposure.

Indexed as

Adenosine A2 Receptor AgonistsAdenosine A2 Receptor AntagonistsBlotting, WesternCell Line, TumorCell MembraneCell SurvivalColoring AgentsDNA, ComplementaryFullerenesHumansIsomerismMicroscopy, ElectronReal-Time Polymerase Chain ReactionReceptor, Adenosine A1Receptor, Adenosine A2AReceptors, Purinergic P1Adenosine A2 Receptor AgonistsAdenosine A2 Receptor AntagonistsColoring AgentsDNA, ComplementaryFullerenesReceptor, Adenosine A1Receptor, Adenosine A2AReceptors, Purinergic P1RNATetrazolium SaltsThiazolesthiazolyl blueAdenosine receptorfullereneSK-N-MC cells

Identifiers

PMID22816023
PMCPMC3369736
OpenAlexW2063275794

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.